Multi-Treatment Designs
GeoSC supports several treated geographies, but interpretation and computation change.
The top-level effect is joint across the treated set; it is not a separate ATT
for each geography. Placebo assignments must contain the same number of control
units as the treated set, giving possible assignments.
Each physical control contributes one residual path, so two treated units and
ten controls give 45 assignments. Controls with identical residual values
remain separate geographies. An assignment cannot contain the same geography
twice, although separate sampled assignments can repeat.
SparseSC work can grow rapidly, so sparse_sc_max_n_pl may trigger sampling.
There must be at least as many controls as treated units. This subset feasibility rule does not establish sufficient p-value resolution or satisfy the separate cross-fitting requirements; a larger control pool may be needed.
Power injects the same absolute effect path into every treated unit, based on
the pooled treated pre-period mean. This is not unit-specific proportional lift.
When treated units have very different outcome levels, supplement the standard
run with a carefully labelled sensitivity analysis or avoid describing the
injected effect_size as each unit’s own percentage lift.
All treated units must share one launch date equal to intervention_date.
GeoSC checks supplied dates before excluding cooldown periods and retiming the
estimator to the common measurement start. Staggered dates and a shared date
that differs from intervention_date are rejected. The private SparseSC
estimator also rejects staggered and dose-normalised requests; they require
different assignment rules.
Regenerate multi-treatment p-values, intervals, and power outputs produced before the distinct-geography correction, including runs with a small placebo cap. Earlier construction replicated the control block once per treated unit; a low cap could hide the count mismatch without repairing the reference set. The correction preserves fitted weights and point effects. It does not qualify the placebo exchangeability assumptions or establish simulation calibration.